TABLE 3

Effects of β-blocker therapy in pulmonary arterial hypertension patients: propensity-adjusted outcome analysis

UnadjustedOptimal matching
Mortality OR (95% CI)1.11 (0.75–1.66)1.13 (0.69–1.82)
Clinical worsening events OR (95% CI)1.01 (0.64–1.60)0.96 (0.55–1.68)
Transplant OR (95% CI)1.02 (0.46–2.23)1.17 (0.39–3.47)
Hospitalisation OR (95% CI)0.89 (0.60–1.32)1.06 (0.66–1.32)
NYHA class change from baseline
 Year 1-0.12 (-0.35–0.10)0.03 (-0.24–0.30)
 Year 30.11 (-0.53–0.31)0.07 (-0.53–0.40)
 Year 50.24 (-0.01–0.49)0.17 (-0.15–0.48)
6MWD m
 Baseline-15 (-42–12)-3 (-36–30)
 Follow-up-15 (-50–20)-23 (-69–22)
  • Data are presented as mean difference (95% CI), unless otherwise stated. NYHA: New York Heart Association; 6MWD: 6-min walking distance.